Selected Publications

Lerman BJ, King M, Mody R, Onyeama SJ, Marachelian A, Cash T, Federico SM, Granger M, Desai AV, Shusterman S, Foster JH, Sokol E, Greer C, Streby K, Meany HJ, Vo KT, Macy ME, Bagatell R.: Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High-Risk Neuroblastoma: A Multi-Institutional Retrospective Study. Pediatr Blood Cancer Mar 2026.

Jones E, Naranjo A, Winestone LE, Umaretiya PJ, Aziz-Bose R, Kelly CA, Newman H, Zheng DJ, Greengard E, Bagatell R, DuBois SG, Bona K.: Collecting Social Determinants of Health in a Children's Oncology Group Trial for High-Risk Neuroblastoma. JAMA Netw Open 9: e260419, Mar 2026.

Lin M, Chen JJ, Bagatell R, Shaaban SG, Lerman BJ, Shusterman S, Ioakeim-Ioannidou M, Yock TI, Catalano PJ, Elhalawani H, Dusenbery KE, Vo KT, Huang MS, Friedmann AM, Diller LR, Marcus KJ, MacDonald SM, Terezakis SA, Braunstein SE, Hill-Kayser CE, Haas-Kogan DA, DuBois SG, Liu KX.: Characterization of Clinical Outcomes for Patients with Relapsed High-Risk Neuroblastoma After Autologous Stem Cell Transplant and External Beam Radiotherapy. Cancers (Basel) 18: 520, Feb 2026.

Werr L, Boland J, Petersen J, Iglesias F, Höppner S, Bartenhagen C, Rosswog C, Hellmann AM, Kahlert Y, Hemstedt N, Ibruli N, Dammert MA, Decarolis B, Werner JM, Malchers F, Schramm K, Witt O, Beiske KH, Rognlien AGW, Gunnes MW, Langenberg KP, Molenaar J, Bernkopf M, Taschner-Mandl S, Hughes D, George SL, Chesler L, Schulte JH, Barone G, Capasso M, Surrey LF, Bagatell R, Masliah-Planchon J, Schleiermacher G, Grüll H, Westermann F, Schultheis AM, Büttner R, Henssen AG, Eggert A, Peifer M, Shukla NN, Simon T, Hero B, Reinhardt HC, Thomas RK, Fischer M.: Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma. J Clin Invest 136: e189152, Feb 2026.

Hazard FK, Toland AMS, Tan SY, Chiu B, Ikegaki N, Naranjo A, Cohn SL, London WB, Gastier-Foster JM, Ramirez NC, Reshmi SC, Wagner E, Nuchtern J, Asgharzadeh S, Marachelian A, Maris JM, Bagatell R, Park JR, Irwin MS, Hogarty MD, Shimada H.: Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children's Oncology Group. Clin Cancer Res 32: 127-134, Jan 2026.

Desai AV, Naranjo A, LaBarre B, Chen L, Goldsmith KC, Granger MP, States L, Green SG, Trunzo M, Fitzgerald W, DuBois SG, Bagatell R, Park JR, Marachelian A.: A pilot study of chemoimmunotherapy in the postconsolidation setting for high-risk neuroblastoma (ANBL19P1): A report from the Children's Oncology Group. Cancer 132: e70165, Jan 2026.

Hudda Z, Webster A, Anderson E, Badia P, Bagatell R, Bhar S, Bidgoli A, Boyd K, Chaudhury S, Cisneros GS, Craddock J, Davies SM, Desai AV, Drobatz L, Dvorak CC, Elkus H, Fabrizio VA, Foster JH, Fraint E, Freedman JL, Galvez J, Garcia M, Haight A, Higham C, Jodele S, Kamat A, Kaviany S, Lehmann L, Leung K, Lind KT, Llaurador G, Kapadia M, Khazal S, Massi K, Mormann M, Pater L, Rangarajan HG, Rotz S, Sabulski A, Sartain SE, Schoettler ML, Sokol E, Streby KA, Stein M, Verneris MR, Weiss BD, Yazdani S, Zheng D, Dandoy CE.: Acute Toxicities and Early Outcomes of Tandem Autologous Stem Cell Transplantation in Pediatric High-Risk Neuroblastoma: A Multicenter Study. Transplant Cell Ther 2026.

DuBois SG, Moreno L, Bagatell R, Cheung NK, Gray JC, Locatelli F, Reynolds CP, Rossig C, Sondel PM, Drezner N, Kholmanshikh O, Bird N, Day L, Ludwinski D, Scobie N, Pons Sanz V, Ball S, Hammer B, Alvarez Rojo I, Meager D, Sveistrup J, Berlanga P, Casanova M, Glade-Bender J, Macy M, Morgenstern DA, Owens C, Weigel BJ, Pappo A, Nysom K, Anderson J, Ligas F, Lesa G, Donoghue M, Karres D, Vassal G.: Paediatric Strategy Forum for medicinal product development of agents targeting GD2 ganglioside in children and adolescents with cancer. Eur J Cancer 231: 116093, Dec 2025.

Rebernick RJ, Choi JE, Hesse C, Hosseini N, Chu A, Zhou J, Ning Y, Wang R, Cao X, Irwin M, Wu YM, Kumar C, Rabah R, Bagatell R, Chinnaiyan AM, Mody R, Cieslik M.: Chromosomal instability degrades developmental phenotypes essential for anti-GD2 immunotherapy outcomes in high-risk neuroblastoma. Cell Rep Med 6: 102375, Oct 2025.

Cohn SL, London WB, Schleiermacher G, Moreno L, Ambros IM, Ambros PF, Bagatell R, Popovicmd MB, Beiske KH, Berthold F, Birz S, Brisse HJ, Brodeur GM, Brock PR, Burchill S, Eggert A, Federico SM, Fischer M, Furner BT, Hero B, Machin D, Kamijo T, Matthay KK, Nakagawara A, Naranjo A, Pötschger U, Valteau-Couanet D, Watkins MT, Irwin MS, Volchenboum SL, Park JR, Pearson ADJ.: International neuroblastoma risk group consortium: a model of a networking for rare cancers. J Natl Cancer Inst Aug 2025.